Botulinum toxin improves forehead scars after Mohs surgery: A randomized, double-blinded, controlled study - 15/03/22
Doi : 10.1016/j.jaad.2021.03.110
Matthew J. Lin, MD a, ⁎ 
, Daniel M. Bernstein, MD a, Richard L. Torbeck, MD a, Danielle P. Dubin, BA a, Joshua D. Rosenberg, MD b, Hooman Khorasani, MD a
, Daniel M. Bernstein, MD a, Richard L. Torbeck, MD a, Danielle P. Dubin, BA a, Joshua D. Rosenberg, MD b, Hooman Khorasani, MD a a Division of Dermatologic Surgery, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
b Division of Facial Plastic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York
∗Correspondence to: Matthew J. Lin, MD, Icahn School of Medicine at Mount Sinai, 234 East 85th Street, 5th Floor, New York, NY 10028Icahn School of Medicine at Mount Sinai234 East 85th Street, 5th FloorNew YorkNY10028
| Funding sources: Allergan PLC provided samples of onabotulinumtoxinA for use in the study. |
|
| IRB approval status: Approved by the Institutional Review Board of the Mount Sinai School of Medicine, GCO 15-1093, NCT02623829. |
|
| Reprints not available from the authors. |
© 2021
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 86 - N° 4
P. 964-966 - avril 2022 Retour au numéro
Article précédent
- Prevalence of female pattern hair loss in a multiracial population
- Giuliane Minami Tsutsui, Paulo Müller Ramos, Hélio Amante Miot
- Clinical factors impacting clear margins of primary melanoma in situ with conventional excision in a retrospective cohort
- Brianna Olamiju, Kathleen C. Suozzi, David J. Leffell, Sean R. Christensen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?